Gene therapy trailblazer Ark Therapeutics was dealt a blow last December, when the European Medicines Agency (EMEA) rejected the London-based company's marketing application for its adenoviral ...
In August, gene therapy's turbulent ride through the clinical rapids took a new twist as Ark Therapeutics released positive top-line results from a phase 3 trial of its adenoviral gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results